BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31064345)

  • 1. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
    Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
    BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
    Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
    Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden.
    Fortea J; Prior M
    J Med Econ; 2013; 16(3):329-41. PubMed ID: 23216014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
    Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
    J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of irritable bowel syndrome in China.
    Zhang F; Xiang W; Li CY; Li SC
    World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort.
    Herrick LM; Spalding WM; Saito YA; Moriarty J; Schleck C
    J Med Econ; 2017 Mar; 20(3):273-279. PubMed ID: 27783533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.
    Guerin A; Carson RT; Lewis B; Yin D; Kaminsky M; Wu E
    J Med Econ; 2014 Aug; 17(8):577-86. PubMed ID: 24811855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden.
    Heidelbaugh JJ; Stelwagon M; Miller SA; Shea EP; Chey WD
    Am J Gastroenterol; 2015 Apr; 110(4):580-7. PubMed ID: 25781368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
    Buono JL; Mathur K; Averitt AJ; Andrae DA
    J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.
    Singh P; Staller K; Barshop K; Dai E; Newman J; Yoon S; Castel S; Kuo B
    World J Gastroenterol; 2015 Jul; 21(26):8103-9. PubMed ID: 26185382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Societal costs for irritable bowel syndrome--a population based study.
    Hillilä MT; Färkkilä NJ; Färkkilä MA
    Scand J Gastroenterol; 2010 May; 45(5):582-91. PubMed ID: 20166844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
    Lacy BE; Patel H; Guérin A; Dea K; Scopel JL; Alaghband R; Wu EQ; Mody R
    PLoS One; 2016; 11(4):e0154258. PubMed ID: 27116612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome.
    DiBonaventura M; Sun SX; Bolge SC; Wagner JS; Mody R
    Curr Med Res Opin; 2011 Nov; 27(11):2213-22. PubMed ID: 21951105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR).
    Taylor DCA; Abel JL; Martin C; Doshi JA; Essoi B; Korrer S; Reasner DS; Carson RT; Hunter AG
    J Med Econ; 2020 Oct; 23(10):1072-1083. PubMed ID: 32696684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden attributable to functional bowel disorders in Iran: a cross-sectional population-based study.
    Moghimi-Dehkordi B; Vahedi M; Pourhoseingholi MA; Khoshkrood Mansoori B; Safaee A; Habibi M; Pourhoseingholi A; Zali MR
    J Dig Dis; 2011 Oct; 12(5):384-92. PubMed ID: 21955432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
    Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
    Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of irritable bowel syndrome in the UK and US.
    Maxion-Bergemann S; Thielecke F; Abel F; Bergemann R
    Pharmacoeconomics; 2006; 24(1):21-37. PubMed ID: 16445300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.